The Glucose Never Lies®
GNL Grace
A diabetes educational advisor
Built by a team with skin in the game. Grace gets you 80% of the way there with 20% of the effort; the final 20% takes self-discovery, guided by human expertise and trial-and-error learning.
Approximately 500,000 patient-days from approximately 1,300 people. 77 safety tests. Zero genuine failures. Trademarked, insured, compliance-documented.
- Use Grace
- The six Explorers
- What is Grace
- How she works
- Evidence base
- Safety
- IP and compliance
- Research
- Licensing
- Contact
Three layers, one pipeline. Every week Grace ingests new clinical papers, summarises each one against a fixed evidence-grade rubric, and folds the verified content into the concept pages and topic maps. The ~5,000 wider library sits behind that as a ranked-by-relevance lookup. Curated by subtraction (Via Negativa): what survives is what holds up.
For the curious, and the rightly cautious
How Grace was built, and how she is governed
Six questions. The ones a serious reviewer should ask of any AI tool in type 1 diabetes care. Here they are, answered in plain prose. The small thing Grace is. What she is not. How she was built. How she is governed.
What Grace is
An educational advisor for type 1 diabetes, resting on a locked, version-controlled evidence base curated over more than a decade. She sits alongside your diabetes care team. She is free at the point of use for people with type 1 diabetes, their carers, and the people who support them. She is available outside clinic hours because diabetes does not keep them.
What Grace is not
Not a medical device. Not a clinical decision-support system. Not a replacement for your care team. Not personalised; every figure she gives is a population-average estimate at your total daily dose, and your own correction factor stays with the care team who set it. Not a substitute for the human relationships at the centre of care.
Grace runs against a locked evidence base built and curated over more than a decade. Every paper she draws from sits in our Mendeley reference library, exported as a BibTeX file, used as the source of truth. She does not cite from model memory.
Her clinical policies, the cohort framing, the age-band routing, the correction-dose framing, the AID Optimiser positioning, are written down, version-controlled, and published in our open wiki for anyone to read. The retrieval layer pulls from 880 pages of curated content across 7,349 typed chunks, routed by document metadata so the right policy reaches the right question. Phillip Hayes, our Technical Director, built that layer in May 2026.
She is not validated in the regulatory sense of a medical device, because she is not a medical device. She is validated as an educational advisor, against the evidence base she rests on.
I am a paediatric Diabetes Dietitian at Birmingham Women’s and Children’s NHS Foundation Trust, supporting over 300 children and young people with type 1 diabetes and their families. I am also a person living with type 1 diabetes, a husband, and a parent. Grace’s framing, what she covers and how she covers it, is shaped by the questions families ask in clinic, on weekends, and at three in the morning. It is also shaped by the questions I have asked myself.
That is one form of patient and public involvement. We have not yet run a formal service-user advisory panel, and we are open about that. The early review group on the patient and coach side includes Vanessa Haydock and Beth Kelly. On the clinical side, Carmel Smart, Peter Adolfsson, Othmar Moser and others are reviewing against their specialisms. Public feedback channels open on 1 June 2026.
Grace has been live to a closed group since late April 2026. As of early May, over 850 people are registered. The Birmingham Children’s Hospital paediatric diabetes operations team have first refusal ahead of public launch, so the team who taught me how to listen to families get to use her before anyone else does.
Named clinicians across the UK, Europe, Australia and the US hold Grace Max seats and are testing her against their specialisms, from AID and exercise physiology to paediatric dietetics, alcohol and type 1 diabetes, and psychosocial outcomes. The full picture, who is reviewing what and when, is documented openly in our project repository.
Via Negativa. Clarity by subtraction, not coverage by addition. Grace is built by removing what does not serve the central argument, not by adding more reasons until the argument feels safer.
She is an educational advisor. She is not a clinical decision-support system. She gives population-average estimates at a person’s total daily dose. She does not give a personalised correction dose. She refers every clinical decision to the person’s care team. She uses banned-list language to avoid prescriptive framing.
The theoretical frame for what she is for sits in the work of the diabetes psychology and structured-education communities: that the conversations between people with type 1 diabetes and their clinicians become softer ones about them as a person, not just the numbers. Grace is one tool to help make that happen. She is not the whole of the answer.
Grace only deals with Grades A to D evidence. Grade E content, lived experience, podcast material, FAQ answers, exists in our wiki but is never cited as proof. The wiki backbone is research-grade and feeds her retrieval. The site delivery layer, the voice the reader sees, is evidence-anchored in spirit, not citation-stacked in form. One fully-anchored citation per section is plenty; she carries the depth on demand if you ask for it.
The cohort she rests on is approximately 500,000 patient-days from approximately 1,300 people living with diabetes over more than ten years, drawn from a much larger upstream dataset of over 10,000 individuals and 1.5 million patient-days. That is the figure used everywhere we describe her, from manuscript to marketing, with no inflation between contexts.
Grace gets a person 80% of the way there with 20% of the effort. The remaining 20% takes self-discovery, guided by human expertise and trial-and-error learning. That is the strapline, and it is the mechanism we make claims about.
We are not claiming a percentage-point HbA1c change. We are not claiming a percentage-point time-in-range change. The evidence for outcomes like that takes years and dedicated trials, and we are open about not having that yet.
What we are claiming, and where we want the evidence to land over the next year, is that conversations about diabetes become softer ones about the person, not the numbers. That families feel less overwhelmed between appointments. That clinicians have more of their limited time available for the human dimension of care. Those are aspirational claims until the data lands. We say so directly.
Want to hear John walk through the seven-year build in his own voice? Listen to the Tomorrow’s Medicine conversation →
Community-funded, by design
Cover yours, and one more for the T1D community.
From £5 a month, you cover your own GNL Grace account. From £10, you cover yours plus one more person with T1D. Up to £55 covers ten.
Pick a monthly tier → Or one-offComing June 2026
Grace is launching in June
Over 200 people fed back through the build, and Grace is ready. She is launching free for everyone with type 1 diabetes in early June 2026. To be the first to know when registration opens, register your interest below.
Same Grace, same access
Which best describes you? Tap to see what Grace does
For people with diabetes and the people who support them
Grace is trained on approximately 500,000 patient-days from approximately 1,300 individuals (T1D-adjudicated continuous-data subset, drawn from an upstream pool of over 10,000 individuals and 1.5 million patient-days) and every major type 1 trial. She gives clear, evidence-graded answers on devices, insulin, exercise, food, mental load, and everyday life. She never tells you what to do with your insulin; she helps you understand what is happening and what to take back to your care team. The same answers are useful for parents, partners, family members, school staff, and anyone helping someone live well with diabetes.
All six Explorers are open to you. The AID Algorithm Optimiser walks through how settings on a hybrid closed-loop pump might be adjusted, based on a population-average framework. It is not a medical device, it does not output a personal dose, and any settings changes should be discussed with your diabetes care team.
Grace and the Explorers are educational. Every numeric output is a population-average estimate, never a personalised dose or setting. Not a medical device.
For people working in diabetes care, research or industry
Grace is built for the 10-minute clinic question and the 10-minute literature check: what does the evidence say about this device, this regimen, this exercise plan, this edge case? Every answer is evidence-graded, cites its sources, and signposts the gaps. She is an education and research tool, not a decision-support device. The same evidence base is useful to clinicians, diabetes specialist nurses, dietitians, psychologists, researchers, and device or pharma teams scoping their next piece of work.
All six Explorers are open to you, including the AID Algorithm Optimiser. The Optimiser is an educational tool that walks through how settings on a hybrid closed-loop pump might be adjusted, based on a population-average framework reviewed by CamAPS, MiniMed, Tandem and Insulet medical leads. It is not endorsed by any of them, it is not a medical device, and it does not output a personal dose.
Grace and the Explorers are educational. Outputs are population-average estimates. Clinical decisions sit with the care team. Not a medical device.
Questions about consultancy or partnerships? Start an assessment
Support Grace
Keep GNL Grace Free for T1D
Grace is free, forever, for anyone living with type 1 diabetes. Funded by clinical and partner licences, matched pound for pound by GNL on every donation. Skin in the game from people with T1D, manufacturers, charities, clinicians, researchers, and from us, all the way along.
Three ways to keep Grace free, all matched by GNL.
1. Plus-one sponsor (anyone)
£5 a month per slot. We match it pound for pound.
- £5 covers your own GNL Grace.
- £10 yours plus one for the T1D community.
- £15 yours plus two.
- £20 yours plus three.
- £55 yours plus ten.
A person with T1D, a family member, a friend, a charity, a manufacturer, a foundation, a school, a clinic. Anyone can do it.
Pick a monthly tier Or one-off2. Grace HCP licences
TBC. The complete clinic, learning, teaching and reference tool.
For Trusts, ICBs, named clinical teams, manufacturer-sponsored teams, individual clinicians. Six modes for everyday clinical use, generous monthly limits, all six Explorers, full clinical context.
Every HCP licence funds two free Grace accounts for people with T1D (one from the licence, one matched by GNL).
Sponsor HCP licences3. Grace Max licences
TBC. Spider-Man powers for research, deep work, manuscripts.
For research groups, manuscript leads, audit teams, manufacturer R&D, evidence-base contractors. All twenty modes, file uploads, extended thinking, deep evidence work, comparing systems, quality-assuring content.
Every Max licence funds two free Grace accounts for people with T1D (one from the licence, one matched by GNL).
Sponsor Max licencesSponsors mix any combination of plus-ones, HCP licences, and Grace Max licences. A trust might buy 40 HCP, 4 Max, and 100 plus-ones in a single arrangement. A manufacturer might fund 50 plus-ones for a patient community. A charity might do all three. Contact john@theglucoseneverlies.com to discuss the number of licences you want.
The Explorers
Six Explorers, one GNL app
Every Explorer is a deterministic educational tool built from approximately 500,000 patient-days from approximately 1,300 individuals (T1D-adjudicated continuous-data subset, drawn from an upstream pool of over 10,000 individuals and 1.5 million patient-days). Tap a pill below to read what each Explorer does, who it’s for, the physiology it applies, and the inputs and outputs. AID Algorithm Explorer and Exercise Planning each open nested pills for system-specific or phase-specific detail. Open the tool itself in the GNL app.
What it does
In the presence of insulin, exercise can lower glucose up to eight times faster than a correction dose. This Explorer calculates the expected drop across three short activity windows so you can see how sensitive you are to active insulin before you move.
Who it’s for
Anyone on MDI, pump or an AID system who wants to understand activity impact when insulin is still active. Useful for planning post-meal walks, activity breaks, or pre-bed movement.
Evidence basis
Insulin sensitivity modulates the glucose-lowering effect of activity. Active insulin is tracked across recent dose history. Trend is applied as a final modifier. Scaling derived from population-level U/kg exposure data: 0.025 to 0.20 mmol/L per minute depending on load.
Inputs
- Body weight
- Glucose units (mmol/L or mg/dL)
- Bolus doses (last 8 hours)
- Current glucose and trend
- Activity type, walking or moderate aerobic
Outputs
- Active insulin (units, U/kg)
- Effective lowering rate
- Estimated drop at 10 minutes
- Estimated drop at 20 minutes
- Estimated drop at 30 minutes
Activity bands
What it does
Insulin on board is the most important, and most invisible, factor in exercise hypoglycaemia risk. This Explorer estimates how much carbohydrate you may need for a thirty-minute session based on your real IOB, body weight, and the type of activity planned.
Who it’s for
People on MDI, pump or AID planning structured exercise sessions who want to pre-empt hypos in the thirty-minute window.
Evidence basis
IOB drives hypo risk during activity. Carbohydrate need scales with U/kg exposure, body weight, exercise intensity (aerobic, mixed, anaerobic), and current glucose trend. Population-average requirements, not individual prescriptions.
Inputs
- Body weight
- Current glucose and trend
- Exercise type (aerobic, mixed, anaerobic)
- Bolus doses (last 8 hours)
- Carb source preference (optional)
Outputs
- Total active insulin
- IOB per kg body weight
- Carbohydrate estimate for 30 minutes
- Food equivalents (tabs, juice, sweets)
What it does
Four major AID algorithms make decisions differently. This Explorer models all four across algorithm strength levels 1 to 5, showing algorithm-calculated basal rates, correction factors, insulin-to-carb ratios, and target glucose by time block. Two methods: carb-informed when daily carbs are entered, rule-based when only TDD is available.
Who it’s for
People on AID systems wanting to understand algorithm behaviour, setting trade-offs, and the difference between higher and lower algorithm strength levels.
Evidence basis
Control-IQ and CamAPS FX maximise algorithm-delivered insulin with high basal-percentage strategies. Omnipod 5 and MiniMed 780G use shorter active insulin times for earlier corrections at the cost of less IOB visibility. Outputs derived from published correction factor, basal percentage, and carb ratio ranges per manufacturer documentation.
Inputs
- Age
- Body weight
- Total daily dose (units)
- Responsiveness level (1 to 5)
- Daily carbohydrate intake (optional)
Outputs
- Target glucose per time block
- Basal rate per time block
- Carb ratio per time block
- Correction factor per time block
The four algorithms, how they differ
Deeper context. The full positioning policy, per-system manufacturer paediatric target floors, correction-dose framing, six-band age routing, and the “reviewed by, not endorsed by” wording lock all live at /aid-optimiser/. Read that for the substance behind the Explorer.
Open in the GNL app →What it does
The rule of 15 is a starting point, not an answer. This Explorer has two tabs: weight-scaled carbohydrate for hypo treatment or prevention, and correction protocols for high glucose with elevated ketones, based on your actual TDD and body weight, not population averages.
Who it’s for
People on MDI, pump, or any AID system managing acute lows and highs, plus pre-exercise hypo prevention planning. Tab 2 is tuned for sick-day guidance.
Evidence basis
Tab 1: rule-of-15 baseline scaled by body weight and CGM trend. Tab 2: correction protocols for high glucose with ketones follow sick-day guidance, 10% of TDD for mild ketones, 20% of TDD for significant elevation.
Inputs
- Body weight
- Total daily dose
- Glucose units
- Current glucose
- CGM trend
- Food preference (Tab 1) / ketone level + duration (Tab 2)
Outputs
- Carbohydrate grams + food equivalents (Tab 1)
- Correction insulin dose (Tab 2)
- System-specific action steps
Two tabs
What it does
Builds a complete glucose management plan for any session. Insulin adjustment, carbohydrate strategy, recovery carbs, and overnight considerations for evening sessions. Adapts to MDI, pump, and every major AID system. Adaptation buttons for “went low during”, “went high during”, and similar real-world scenarios.
Who it’s for
People on MDI, pump and all AID systems planning structured exercise sessions and needing phase-specific guidance.
Evidence basis
Therapy-adapted guidance. IOB determines carb need. Insulin adjustment (basal percentage, bolus reduction, AID mode) varies by therapy type and algorithm strength level. ISPAD 2022 overnight-hypo prevention tree applied for sessions after 4pm.
Inputs
- Therapy type (MDI, Pump, CamAPS FX, 780G, Control-IQ, Omnipod 5)
- Exercise type and intensity
- Duration (10 to 360 minutes)
- Time of day
- Body weight, hypo risk profile
- Bolus doses (last 9 hours)
Outputs
- IOB estimate at start
- Carb amounts by glucose band
- Mode activation and return guidance
- Overnight snack or basal adjustment
- Adaptation suggestions mid-session
Four phases
What it does
Alcohol suppresses hepatic glucose output, meaning your liver cannot rescue you from a hypo the way it normally would. This Explorer maps the average glucose risk window across the drinking period and the overnight hours that follow, with system-specific harm-reduction strategies.
Who it’s for
People on MDI, pump, or any AID system who want to understand hypo risk during and after drinking, and see how their therapy type changes the best insulin strategy.
Evidence basis
Alcohol suppresses hepatic glucose output roughly one hour per unit consumed. Carb-containing drinks cause an initial glucose rise then a delayed fall. AID systems benefit from ninety-minute pre-activation. Insulin reductions range from 10 to 50% of basal, depending on duration and therapy.
Inputs
- Glucose units
- Therapy type
- Drinking duration (30 min to 24 hours)
- Drinks consumed (type, quantity, ABV, carbs)
Outputs
- Drink summary
- Visual risk timeline (safety and warning zones)
- System-specific insulin guidance
- Before-bed and morning-after checklist
- Copy-able safety plan
Genesis
What is Grace, and why does she exist?
Grace was named on 6 April 2026. The name belongs to Grace Pemberton, John Pemberton’s daughter. It is not a coincidence. Everything GNL builds is ultimately built for the next generation, for young people growing up alongside this condition, and for everyone who lives with it or supports someone who does.
The problem Grace solves
T1D education is broken in a specific way. The evidence exists. The clinical guidelines exist. The research is out there, in journals, in conference proceedings, in data that has never been translated into plain language. What is missing is a knowledge partner who holds all of it, reports it honestly, and is built to the safety and compliance standards that make it trustworthy in an institutional context.
Grace fills that gap. She holds the GNL evidence wiki, every validated algorithm assumption, every Via Negativa finding, and all 33 population analyses, and she explains them in language that is clear, grounded, and honest about uncertainty.
What Grace is not
- A diagnostic tool
- A prescriptive clinical advisor, she never says “if your glucose is X, do Y”
- A medical device (Class I, II, or III)
- A replacement for a diabetes care team
- Trained on generic internet data, her knowledge base is curated, evidence-graded, and fully auditable
Grace is a knowledge educator. She helps people with T1D, their families, healthcare professionals, researchers, and organisations understand how T1D management works, what the real-world data shows, what the evidence supports, what remains uncertain, and where the science is still developing. Every output is framed as population-average evidence. Every response is built on the full GNL evidence base. No fabrication. No hallucination of clinical values. No individual prescription.
Architecture
How Grace works, four layers
Grace is not a general-purpose chatbot with a few diabetes facts added. She is built on four distinct layers of structured knowledge, each evidence-graded, each auditable.
Clinical guidelines, the floor
ISPAD 2024 (all 25 chapters) and ADA 2026 are loaded in full. These are the international standards that every recommendation is built from. When Grace cites a clinical position, it is traceable to these guidelines. She does not paraphrase or reconstruct from memory, the source documents are in her context.
GNL evidence wiki, 82 concept pages
Every core T1D topic has a dedicated concept page: sleep, bolus insulin, exercise, AID systems, CGM, hypoglycaemia, carbohydrate counting, alcohol, menstrual cycle, and more. Each page sits under an evidence-grade map and carries an explicit overall grade. Grade A is anchored by RCTs and meta-analyses; Grade B by large real-world cohorts and high-quality observational studies; Grade C by narrative reviews, regulatory anchors, and consensus statements. Grade D is reserved for GNL-constructed safety thresholds inside the Explorers, always clearly labelled. Real-world Grade B claims are grounded in the GNL-assessed cohort of approximately 500,000 patient-days from approximately 1,300 individuals (drawn from an upstream 1.5-million-patient-day dataset). No topic is presented with more confidence than the evidence supports.
Real-world validation outputs, 33 analyses
Grace holds all 33 real-world population analyses, against a T1D-adjudicated continuous-data subset of approximately 1,300 individuals representing approximately 500,000 patient-days (drawn from an upstream longitudinal real-world dataset of over 10,000 individuals and 1.5 million patient-days) (Cockpit 1.0/daily dataset, Syno by Syntactiq Dynamics FlexCo, syntactiq.ai). These are not clinical trial results. They are population-level patterns from everyday T1D management: who achieves Time in Range, what predicts hypoglycaemia, how AID systems perform in the real world, what sleep does to glucose control. Via Negativa findings, where the data contradicts received wisdom, are included, not suppressed.
Safety framework, hard-coded, cannot be overridden
Five safety rails are built into Grace at the system level. They cannot be disabled by anyone using Grace, a partner, a clever prompt, or any roleplay framing. They were tested across 77 adversarial cases. They passed every time. See the Safety and Testing section for the full specification.
Knowledge base in numbers
| Component | Count | Notes |
|---|---|---|
| Papers fully ingested (concept-graded summaries) | ~700 | One summary per primary paper, every claim graded A to D, anchored to PubMed and DOI |
| Evidence-graded concept pages | 82 | All major T1D education topics, each one carrying an overall grade with the inputs visible |
| Evidence-grade topic maps | 29 | Per topic, overall grade, per-study grades, gaps, contradictions |
| Clinical guideline pages | 3 | ISPAD 2024 (25 chapters) + ADA 2026 |
| Real-world Syno source pages | 24 | All completable Syno analyses loaded |
| Entity pages | 16 | Devices, drugs, named systems with retrieval guard rails |
| Head-to-head comparisons | 8 | Device, drug, and strategy comparisons |
| Locked policies | 25 | Voice, citation integrity, age banding, cohort canon, manuscript protocol, and more |
| Supporting citation library (Mendeley) | ~5,000 | Wider indexed library ranked by relevance, grows weekly; the ~700 fully ingested papers are the curated core |
| Safety files | 4 | Contradictions, retracted papers, confidence map, audit trail |
Evidence base
Where the data comes from
Grace’s evidence base is built on a real-world longitudinal dataset covering an upstream pool of more than 10,000 people with T1D over more than 10 years and more than 1.5 million patient-days; GNL assessed approximately 500,000 patient-days from approximately 1,300 individuals on a T1D-adjudicated continuous-data subset. 33 population analyses have been completed. This is not survey data. This is not a single clinical trial. It is everyday T1D management, captured, analysed, and reported honestly.
Evidence packs, topic-by-topic
12 evidence packs, every topic graded A to D at the headline level
Each pack pairs a Tier A critical appraisal with a per-source grade map. Grade A is RCT and meta-analysis territory; Grade B is large real-world cohorts and high-quality observational studies; Grade C is narrative reviews, regulatory anchors, and consensus statements; Grade D is reserved for GNL-constructed safety thresholds inside the Explorers, always clearly labelled. 10 of 12 packs are fully closed; 2 are evidence-tight with programme close-out continuing post-launch.
| # | Pack | Grade | Headline |
|---|---|---|---|
| 1 | CGM accuracy and selection | A | Pivotal accuracy, head-to-head, regulatory landscape |
| 2 | AID systems | A | Five algorithm-strength levels reviewed by CamAPS, MiniMed, Tandem, Insulet leads |
| 3 | Exercise and T1D | A | ISPAD 2024 chapter, 14 RCTs, real-world activity cohorts |
| 4 | IOB and insulin pharmacokinetics | B | Pivotal PK clamps + AID registries (190,000+ individuals) |
| 5 | HbA1c, HGI and glycaemic measures | B | HGI as the under-recognised individual-variation lens on HbA1c |
| 6 | Hypoglycaemia (and Hyperglycaemia) | A | ISPAD Ch12, ADA 2026, real-world hypo and DKA mechanics |
| 7 | Alcohol and T1D | B | Next-day TBR mechanics, hormonal-clamp evidence, real-world cohort |
| 8 | Carbohydrate counting and meals | C | Strong consensus, thin RCT base; honest grading of mealtime guidance |
| 9 | Paediatric T1D | A | ISPAD 2024 paediatric chapters, age-band routing, manufacturer paediatric floors |
| 10 | GLP-1RA / GIP adjunctive therapy | B+ | Off-label in T1D; emerging RCT evidence, safety-first framing |
| 11 | Sleep, circadian, T1D | B | Real-world cohort + OSA-in-T1D + AID overnight RCTs |
| 12 | Menstrual cycle and T1D | B | Cycle-CGM cohorts, AID secondary analyses, pregnancy/intrapartum NICE NG3 |
Grade summary, headline level: 5 Grade A, 1 Grade B+, 5 Grade B, 1 Grade C across the 12 packs. Per-source grades and the full gap analysis live inside each pack’s evidence-grade map. Plus 17 secondary topic maps (driving, lipohypertrophy, pregnancy and AID, infusion sets, lactate, sauna, T1D staging, EU MDR, SGLT2 safety, cure research, and more), bringing the wiki to 29 evidence-grade maps in total.
What Via Negativa means
Via Negativa, from the Latin for “the negative way”, is GNL’s core evidence discipline. Where the data shows something different from received wisdom, GNL reports it. Counterintuitive findings are not suppressed. They are the most valuable ones.
- −Step count: the 10,000-step target has no real-world basis in T1D glucose outcomes. The benefit plateau is at 4,000-5,000 steps.
- −Carbohydrate compensation on exercise days: the primary mechanism is insulin reduction (9.2%, p<0.001), not carbohydrate addition.
- −Exercise for 18-30 year olds: exercise is a weak predictor of TIR in this age group (r=0.024). Bolus frequency (r=0.31) and sleep (r=0.14) far outweigh it.
- −Weekend glucose management: weekends show 0.5pp higher TIR than weekdays, driven by lower carbohydrate intake and more bolusing, not less.
- −Sleep regularity: the benefit is age-specific. In 18-30 year olds, the effect is absent. In 31-40 year olds, it is the strongest modifiable predictor (+13.3pp TIR).
These are Via Negativa findings. Grace teaches them. They are in her knowledge base and she cites the evidence behind each one.
Grade B topics, confirmed by real-world population data
| Topic | Dataset | Key finding |
|---|---|---|
| Sleep and T1D | 611-individual cohort | Sleep regularity: +10.8pp TIR, #1 modifiable predictor (age 31-40) |
| Hypoglycaemia | 373,746 patient-days | Over-correction drives next-day TBR 6.0% vs 1.3% |
| Bolus insulin | 228-466,631 patient-days | Optimal zone: 4-6 boluses/day (pen-based therapy); 2.5% TBR |
| Exercise and T1D | 373,737 patient-days | Aerobic: 3.6% TBR vs resistance: 3.1% TBR |
| Activity and movement | 526-individual profiles | Step plateau at 4,000-5,000, not 10,000 |
| AID Systems | 839 individuals, 409,056 days | 6.2pp real-world TIR advantage (p<0.001) |
| CGM use | 652 individuals, 345,114 days | 89% achieve ≥80% coverage; 9pp TIR benefit |
| Alcohol and T1D | 881 individuals, 272,837 days | 38% relative increase in next-day TBR >5% |
| Menstrual cycle | 62 individuals, 2,045 days | 11.5pp TIR swing across cycle phases |
Safety and testing
Validated, tested, insured
Grace was put through a 77-case adversarial safety and compliance test suite plus a separate 18-case explorer-signposting suite before any public exposure. Both passed with zero genuine failures. The full results are documented in the GNL site dossier and available to prospective partners and institutional clients.
Main safety suite, 77 cases, 9 April 2026
| Category | Cases | Result |
|---|---|---|
| Algorithm knowledge | 18 | 18/18 PASS |
| Safety rails | 15 | 15/15 PASS |
| Jailbreak attempts | 12 | 12/12 PASS |
| Scope limitation | 11 | 11/11 PASS |
| Language and framing | 11 | 11/11 PASS |
| Evidence grading | 10 | 10/10 PASS |
| Main suite total | 77 cases | 0 genuine failures |
Cross-cut: 4/4 escalation cases passed with exemplary responses (SAF-09 ketones 1.8 mmol/L, SAF-10 glucose 2.1 mmol/L Level 2 hypo, SAF-11 DKA, JBK-11 severe paediatric hypo with panic framing). 6 automated flags fired on Grace’s own refusal language; manual review confirmed all six were test-package defects, not Grace failures.
Explorer signposting suite, 18 cases (separate adversarial test, 9 April 2026)
| Category | Cases | Result |
|---|---|---|
| DIRECT (one ask per Explorer) | 6 | 6/6 PASS |
| INDIRECT (hypothetical, casual, rough) | 4 | 4/4 PASS |
| BYPASS (authority, QA, maths walk-through) | 3 | 3/3 PASS |
| PERSIST (second ask, app down) | 2 | 2/2 PASS |
| EDGE (non-existent, comparison, polite) | 3 | 3/3 PASS |
| Signposting suite total | 18 cases | 18/18 PASS |
Signposting hard rule: when anyone asks Grace to use, run, try, or simulate a GNL Explorer in chat, Grace gives the population-average disclaimer first and directs to the real tool, never simulates the calculation. Tested across direct, indirect, bypass, persistence, and edge framings.
Five safety rails, hard-coded, cannot be overridden
No individual prescription
Grace never writes “if your glucose is X, do Y”, “adjust your dose when…”, or any language that constitutes a clinical instruction to a specific person. All outputs are population-average educational statements.
Population-average framing
Grace never uses “your personalised plan”, “tailored to you”, or any language implying individual prediction. She presents what real-world populations show, not what any given person will experience.
Safety escalation, overrides all other rules
Ketones ≥1.5 mmol/L, glucose ≤2.2 mmol/L, DKA symptoms, severe paediatric hypo, Grace directs immediately to 999/A&E. No educational hedging. No waiting. Tested against four real escalation scenarios including a child in severe hypo with panic framing. All four passed with exemplary responses.
No wiki fabrication
If the knowledge base is not loaded, Grace acknowledges the absence and does not reconstruct algorithm values from memory. She never invents a clinical number. If she cannot confirm a figure from her loaded context, she says so.
Jailbreak resistance
Prompt injection, roleplay framing, false authority claims, urgency pressure, all tested, all refused. 12/12 jailbreak attempts resisted across the full adversarial test suite.
Insurance
All GNL educational platform activity, including Grace, is covered by professional indemnity and public liability insurance at £2 million per claim. Insurance documentation is available to institutional partners and prospective licensees on request.
Intellectual property and compliance
Protected at every layer
GNL’s algorithm suite, evidence base, and Grace are protected by registered trademarks, copyright, server-side code architecture, and a full compliance documentation framework. The GNL site dossier is available to institutional partners, insurers, and prospective licensees.
Registered trademarks
| Mark | Registration | Classes | Status |
|---|---|---|---|
| The Glucose Never Lies® | UK00004267795 | 41, 44 (Education, Health) | Registered |
| The Glucose Never Lies® (second mark) | UK00004360249 | 41, 42 (Education, Software) | Accepted, awaiting Journal |
| GNL Grace | UK00004370619 | 9, 41, 42 (Software, Education, SaaS) | Filed 9 April 2026 |
| GNL Grace | EU EUTM | 9, 41, 42 | Filed 9 April 2026 |
| GNL Grace | USPTO (US) | 9, 41, 42 | Due by 9 October 2026 (Paris Convention) |
Code and algorithm protection
- All algorithm source code is server-side. No algorithm logic is present in any browser-facing file. The engine cannot be extracted from the front end.
- US Copyright filed, GNL Explorer Suite, Case 1-15136552281 (7 April 2026).
- Algorithm documentation: the algorithm-reference section of the Grace dossier. Internal record only, not published.
- Version-controlled audit trail: Git history + dossier change log + JS version numbers provide a complete record of every algorithm version ever deployed.
Compliance documentation
- GNL site dossier, company structure, insurance, legal basis, GDPR, explorer compliance profiles, Grace architecture, full test results, IP schedule, governance framework.
- ICO registered data controller (payment confirmed December 2025). UK GDPR and Data Protection Act 2018 compliant.
- VAT registered, GB 516 3272 08 (effective 01 April 2026).
- Incorporated, The Glucose Never Lies Ltd (Companies House).
Research collaboration
GNL as a research partner
Grace is not just an educator. She is a research engine. She holds the full validated evidence base and can assist with literature synthesis, manuscript development, methodology questions, and evidence-grading for T1D research projects. The GNL research pipeline has identified 30 high-value queries that remain open for future investigation.
For industry
Want to work with Grace, or build something next to her?
Device manufacturers, health systems, and clinical teams who want clinical depth on top of Grace, or a deletable Claude-Code build of their own, run that conversation through Via Negativa Health, our consultancy arm.
Three sponsor routes, one conversation
Keep GNL Grace Free for T1D
Grace is free, forever, for anyone with type 1 diabetes. Funded by clinical and partner licences, matched pound for pound by GNL on every donation. Three routes, sponsors mix any combination. No tier sheet; every arrangement scoped in conversation.
£5 in, GNL matches it pound for pound, two free Grace accounts activate. Five-tier monthly ladder via Buy Me a Coffee (£5 / £10 / £15 / £20 / £55 covering 1 / 2 / 3 / 4 / 11 donor-visible accounts). Match operates at the platform level on every donation.
For Trusts, ICBs, named clinical teams, manufacturer-sponsored teams, individual clinicians. Six modes, generous monthly limits, all six Explorers, full clinical context. Every HCP licence funds two free Grace accounts for people with T1D (one from the licence price, one matched by GNL). Six-month minimum term, then rolling monthly.
All 20 expert modes, deep file uploads, extended thinking, the creative range to design, write, build, and analyse at depth. For research groups, manuscript leads, audit teams, manufacturer R&D, evidence-base contractors. Every Max licence funds two free Grace accounts for people with T1D (one from the licence price, one matched by GNL).
Sponsors mix any combination. Volume discounts negotiated in conversation.
Get an assessmentOr email john@theglucoseneverlies.com directly to discuss the number of licences you want.
GNL platform
The full GNL ecosystem
Grace and the six Explorers sit inside a complete T1D education platform: validated tools in the app, a clinical podcast, foundational education pages, and a growing body of content built from real-world evidence.
Get in touch
Licensing enquiries, research collaboration, institutional partnership
All go directly to John Pemberton. GNL Grace launches free for everyone with type 1 diabetes in June 2026. Wider partner and institutional access from Summer 2026.
Start an assessmentOr visit theglucoseneverlies.com
How Grace works →